TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

M Piccart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.